
Sign up to save your podcasts
Or


Many conditions can elevate or depress the intracranial pressure (ICP) of fluid pushing on the brain, potentially seriously impacting patient health.
However, the only ways to measure ICP require specialized invasive techniques that are too risky for most patients.
In Episode #26 of the MedTech Speed to Data podcast, Key Tech’s Andy Rogers talks with Ryan Myers, CEO and Co-founder of CranioSense, about developing portable, non-invasive ICP measurement technologies.
The National Institutes of Health spends about $42 billion on medical research each year, but less than one-eighth of that money is spent specifically on women’s health. That may come as a bit of a shock, given that women make up a majority – about 51% – of the population. This underserved market is a huge economic opportunity for med tech companies.
That’s what Holly Rockweiler discovered as a Fellow at the Stanford Byers Center for Bio Design. So she put her background in biomedical engineering to work and started Madorra Medical, developing solutions to improve the vaginal atrophy and dryness that women experience after menopause or breast cancer. Madorra’s flagship product is a handheld home-use device that uses ultrasound to rekindle the body’s natural moisture-producing capability. The FDA has granted it breakthrough device designation
The first randomized trial has been published, and a second one is on the way, and the company is now working toward the next set of data. Here in Episode #24, Madorra CEO Holly Rockweiler and Andy Rodgers talk about how that data is helping to blaze new trails in women’s health.
Need to know:
The nitty-gritty:
Vaginal dryness resulting from vulvovaginal atrophy (VVA) affects over half of post-menopausal women and is also common among breast cancer survivors due to treatments that cause estrogen levels to drop. Symptoms include soreness, irritation, pain, increased urinary tract and yeast infection rates, and pain with sexual intercourse.
Today, the standard treatment for menopausal symptoms is estrogen therapy. But that comes with risks: breast cancer, heart attack, and stroke. The quandary for doctors and patients alike is whether the benefits of pharmaceutical treatment outweigh the risks. For some patients, the risks are too significant and estrogen therapy is not recommended.
By putting data to work, Madorra created an ultrasound solution that stimulates natural moisture production and eliminates these risks. Madorra’s hand-held external device, used on regular basis for 8 minutes, has been producing significant results in 1 to 3 weeks. The device is shaped to be intuitive as possible to fit naturally and is used with disposable proprietary hydrogel. Safety is always a key issue, and the wide variety of literature on ultrasound therapies – including the fact that it’s used on pregnant women – has instilled confidence in patients and clinicians alike.
Data that made the difference:
Market data from the Stanford BioDesign program helped Rockweiler learn to do an analysis of unmet needs, stakeholders, and market dynamics before taking the big leap.
An Institutional Review Board (IRB) feasibility study helped in initial development.
Pre-existing data on ultrasound showed that ultrasound therapy in other uses improved blood flow to treated areas. This key finding indicated that it might work on thin friable vaginal tissue as well.
Patient data revealed how the condition feels to patients and what they wanted in a product.
Bench studies and computer simulations proved invaluable in prototyping.
This story is not only compelling because of the ingenious device itself, but it also reveals a broader story about opportunities in the underserved market of women’s health.
Interesting links:
https://www.madorra.com/
https://www.ispot.tv/ad/1VAi/astellas-pharma-super-bowl-2023-whats-vms
Surgery is not usually considered a spectator sport, but an OR is often filled with the surgical team, colleagues, residents, and medical device clinical representatives, in addition to a patient and equipment. Now Avail Medsystems, based in Silicon Valley, has created a way to increase learning, collaboration, and idea-sharing in the OR – while reducing the headcount – by connecting physicians and care teams to remote experts and device industry representatives during medical procedures.
The Avail surgical telepresence platform is a hardware and software platform that enables instant, two-way audio/visual communication with high-definition video, surgical imaging views, and even telestration capabilities.
In Episode #23, Andy Rogers of Key Tech talks with James Domine, CTO at Avail MedSystems, about how data-driven surgical procedures are facilitating collaboration and creating better outcomes.
Need to know:
The nitty-gritty
The Avail platform connects inside and outside the OR and allows viewers to customize their own experience. This way, clinical specialists, additional physicians, residents, and advisors watching the surgery can be remote but still actively participating and sharing with the surgical team. Med-tech research and development teams can sit in on the action, too, enabling collaboration on device development and creating faster product design cycles.
The complete hardware and software package features a palette of high-tech features, including hi-def video, GigE Ethernet port, built-in dialing for calling remote contacts, and medical imaging. The system is on a wheeled cart, with a camera on a manual boom arm, so surgery can be viewed from various angles. The audio system streaming is custom-built for the OR to reduce background noise from machines and equipment.
Avail is a data nexus – not only capturing real-time data from the surgical procedure itself – but archiving and enabling machine learning to help improve subsequent procedures and outcomes.
Audiovisual data - the remote app works with an iPad or laptop. With two-way audio and video, it’s like being in the room — even if you’re thousands of miles away.
Digital data – the system enables digitization of the OR to guide physicians and allow machine learning.
Secure data - Avail is HIPAA-HITECH protected. To enhance security, designers purposefully avoided certain design patterns and third-party platforms.
User feedback - user input ensures that any new feature added will be used, and Avail generates data on reliability, which is logged on Splunk, a data analysis platform that seeks, monitors, and analyzes machine-generated data via a web-style interface.
Through collaborating in real-time, sharing knowledge about surgical techniques, and accelerating the development of new products and procedures, data is connecting a world of medical expertise.
USEFUL LINKs
www.avail.io/
splunk.com
For most MedTech devices, the path to development starts with defining a market need, then creating a technology to fill that need. But sometimes innovation lies in finding a new application for an existing technology. And sometimes the inspiration can come from a totally unexpected place.
Such was the case for Venk Varadan, indie film producer-turned MedTech CEO of Nanowear, a wearable diagnostic device for cardiac patients. Nanowear adapted a unique sensor technology originally designed to provide data-rich sonar for submarines and high-flying aircraft, to create a cloth nanotechnology, which captures and transmits 85+ dimensions of clinical-grade biomarker data from basic skin contact. The fabric has a suede-like texture, which comes from billions of tiny vertical sensors.
Nanowear’s SimpleSense™ is an FDA-cleared wearable A.I.-based remote diagnostic platform. The non-invasive smart fabric collects a variety of metrics including ECG, heart rate variability, respiratory rate, actigraphy, impedance cardiography, thoracic impedance, and cardio-phonography.
Nanowear is one of a handful of ways to track heart rate, blood pressure, and other vital signs for long periods of time. But the big plus is that it’s non-invasive and can be used at home, facilitating patient compliance and, through telehealth, expanding the geography of high-quality care in rural markets.
Andy Rogers of Key Tech gets to the heart of the matter as he talks with Venk about the journey from lab to marketplace.
Need to know:
The nitty-gritty
The primary factors that drive the application of nanosensors in healthcare are their non-invasive ease of use, high signal fidelity, and continuous monitoring capability. Nanowear’s shoulder sash is an easy-to-use multi-metric diagnostic system with state-of-the-art embedded wireless network devices that feeds data to a smartphone, a laptop, or directly to a remote server. This in turn enables a closed-loop digital system for specific machine-learning algorithms built on terabytes of patient data.
Right now, Nanowear is focusing on monitoring congestive heart failure, which affects over 5 million patients in the U.S. With this versatile undergarment, doctors can remotely monitor patients and hopefully reduce expensive hospital visits. For patients, it’s a comfortable, easy way to stay on top of their condition.
The SimpleSense™ fabric is the first cloth that’s FDA 510-cleared, but pioneering the cloth technology was only the beginning. The next challenge was dealing with the “firehose of data” that it generated.
Collecting more data. Nanowear sensors capture 85+ medical grade biomarkers directly from the skin and provide accurate, continuous, real-time assessment of the heart, lungs, and upper vascular system: a more comprehensive picture of patient health.
Managing more data. The cloth technology produces exceptionally high-quality raw signal data. To analyze millions of data points per patient per day, Nanowear had to create proprietary software.
Retaining more data. With machine learning algorithms, Nanowear can track trends in a patient’s cardiovascular health over time, providing clinicians with a tool that enables much more accurate decision-making.
Before any med-tech entrepreneur can bring a product to market, he or she must prove the technology will work reliably. Transforming a nascent technology like digital microfluidics into an intuitive product is not easy. But it doesn’t take a seasoned engineer to understand that you’ll need to evaluate multiple iterations of the device in order to develop a system that will work as intended.
In Episode 21 Andy Rogers and Key Tech Senior Computer Engineer, and Partner, Lei Zong talk about creating test platforms that will collect essential raw data and turn it into useful information to speed up the product development process.
Need to know:
The nitty-gritty:
Medical devices often have humble beginnings. Some may start out in pieces, with off-the-shelf components cobbled together into a benchtop system that simply demonstrates the proof of concept. This is a great shortcut that helps non-software engineers get up and running quickly. But as with any shortcut, there are caveats. Holding off for custom design and testing until later in development isn’t always cost-effective.
Consider this example: you have a PCR test fixture, like those used in COVID tests, to drive a thermal profile with a consumable, and you want to know what’s happening within the platform itself, both with fluid and temperature. You need feedback from the system and software to capture the data. Generally, you have 3 options:
1. Off-the-shelf software, which may lack necessary functionalities or may not be compatible with certain test bed components.
2. A customizable solution such as Key#™ (Key Sharp), a solution that can drive the system and be configured to collect, process, and display the data you need.
3. Develop your own application, which requires time and deep, deep pockets. What’s more, the PC app won’t have any practical commercial use, since you’ll likely need a custom UI to control the product.
The customizable Key#™ solution gives you the most flexibility, budget-wise and performance-wise. Key#™ lets you quickly build the architecture you need with the functionality you want. It allows you to leverage a flexible framework with existing command libraries and gives you the ability to easily add new or custom commands. From there, the user can build scripts to run system protocols and collect data throughout the product development process.
This customizable setup allows the user to easily adjust and test a variety of ranges and performance parameters to make testing fast, reliable, and easy. The user can tweak every parameter at a granular level: control modules, pumps, sensors, temperature ramp rates, and more.
In addition to allowing users to control components at a granular level, the custom message protocol provides a clean and intuitive UI to enable more team members and manufacturing partners, to test devices.
Let’s say you need to control six motors and optical sensors – with Key#™, you can set parameters and go! A program such as Key#™ can give users a graphic image of what the system looks like while collecting and processing hundreds of real-time data points from firmware (such as fluid movement, the temperature at various points in the system, and so on).
As prototypes progress and include more custom features, programs like Key#™ can progress with the prototypes. Key#™ can provide pedigree verification along the way and can also continue running as the foundation for firmware while you enhance the UI. Core functionality remains the same, but the end-user interface is much “dressier.”
To learn more about Key#™, check out our blog “Key Sharp – Key Tech’s Custom Software Tool” or contact us to discuss further.
Everybody likes to feel warm and cozy, but we all know someone that can’t keep themselves warm. This is a particular problem for women who have undergone preventive or therapeutic mastectomies. The implants used in reconstructive surgery often feel cold, literally chilling women to the core.
Kristen Carbone designed Brilliantly Warm, a wearable technology to solve a problem that she had herself: keeping warm following a preventive double mastectomy and implant reconstruction.
A former museum curator, Kristen had no background in engineering or business, but she had a powerful idea. She started with a prototype that was connected to a drill battery, and now has a low profile, wearable technology that delivers safe, natural-feeling warmth to the body.
The device slips easily into any bra and is controlled by an app, making it an almost invisible solution for women who want to feel warmer and more comfortable. Brilliantly Warm was initially designed for mastectomy patients, but since its launch, Kristen discovered it’s also being used by nursing moms, for menstrual cramps, and people with chronic conditions who constantly feel cold.
Here in Episode 20, Key Tech’s Andy Rogers talks with Brilliantly Founder and CEO Kristen Carbone about the hows and whys of Brilliantly Warm and how data – or sometimes the lack of it – shaped the journey from idea to marketplace.
Need to know:
The nitty-gritty
Breast cancer affects about 1 in 8 women in the U.S., and those women who have had a mastectomy and reconstructive surgery often feel cold because implants will actually act as a heat sink and pull heat away from the body’s core.
Until now, women have had to create D-I-Y warming solutions, such as using chemical hand warmers or electric heating pads; these can result in discomfort, burns, and even melted implants, necessitating additional surgery. Therefore, safe temperature control was a critical product requirement for Brilliantly Warm. Once a setting is selected in the app, the wearable warms up, with three temperature settings and a built-in thermometer that ensures it never exceeds 111 degrees F.
In the earliest stages of development, Kristen found herself in a data desert. There was virtually no market research about breast cancer survivors, no research to support the product for investors or even much research on women-founded businesses. * So she did what any enterprising entrepreneur would do: she built a database herself. Through what she terms “shameless networking,” Kristen talked to hundreds of women who had similar experiences and assembled enough anecdotal information to convince investors and customers and get the product off the ground.
Turn anecdotes into science - by assembling a large body of anecdotal information and seeking constant feedback from the breast cancer survivor community, Kristen created compelling evidence of market need.
Use what you got – among the few nuggets of data that Carbone could find was that women have a 30% slower metabolism than men, that 80% of people are willing to use wearable technology, and that feeling warm and comfortable improves productivity, all of which strengthened her case.
Create a data feedback loop for your customers. Kristen talked to hundreds of breast cancer survivors and previvors. Through those conversations, she confirmed the need and recognized that the opportunity to help women feel better was much bigger than a single product. Through a wide range of content on the Brilliantly website, Kristen is connecting with the community of women navigating life after breast cancer with a curated resource of products, services, and information.
After a jump-start into the direct-to-consumer market, Kristen and her team are now three years into R&D with its flagship product, Brilliantly Warm. Though the company is still in the VC stage, the product is approved for HSA and FSA expenditures. Now, they’re exploring the efficiencies of the B2B market and insurance reimbursement. And working on new applications for warming technology.
This is an inspiring story of by-the-bootstraps entrepreneurship. Give it a listen here . You’ll be happy you did.
*According to a February 2021 article in Harvard Business Review, only 2.3% of venture capital funding goes to start-ups founded by women.
Each year, millions of people in the U.S. require some sort of neurosurgery due to injury, disease, or genetic condition. They often undergo multiple procedures and face long, painful recoveries. This inspired Jesse Christopher to start tinkering with his kid’s toys in his garage, which was the beginning of Longeviti Neuro Solutions.
Starting from this humble beginning, Longeviti pioneered the development of a low-profile intracranial device platform in 2016, in partnership with Johns Hopkins: the first customizable platform to address a growing need for patients undergoing complex brain surgeries. Today the company is pioneering new solutions for brain surgeries and has brought several FDA-cleared implants to market.
In Episode 19, Andy Rogers talks with Longeviti Founder and CEO, Jesse Christopher, about the journey from garage to CEO’s office, and the data that helped along the way.
Need to know:
The Nitty Gritty
Longeviti’s Clearfit® disc implants are designed to reconstruct the skull’s natural contour after surgery, and allow for post-operative imaging using ultrasound, instead of more costly MRI or CAT scan procedures. Their InvisiShunt™ supports location and orientation while restoring the natural contour of the cranium for patients with conditions such as hydrocephalus. InvisiShunt is a single-use, sterile implant made to fit different areas of the skull.
These devices are “windows into the brain” that allow doctors to monitor tumors, observe fluid drain, and to use ultrasound instead of more costly MRI or CAT scans for diagnosis and easy access monitoring (ultrasound imaging is not possible on an adult because of the attenuation abilities of the skull).
Of course, a lot of hard data went into the engineering and manufacture of these devices, including material selection, contour, and manufacturing specs. But the secret to Longeviti’s success so far lies in how the company has been able to manage” soft” data.
Market knowledge – before starting Longeviti, Jesse had 20 years’ experience in the field with a Fortune 300 company.
Company culture – in any start-up, you’re flying by the seat of your pants. But establishing a culture that fosters creativity, accountability, and open communication helps build a strong cohesive team. Humility helps.
Education – as with any new technology, real success lies in the ability to educate people about the use and the advantages of your device. Longeviti relies on several pillars:
It’s a marathon run, gathering data to hit critical mass. But these grassroots efforts pay off in real-world terms: research that points to statistical significance, achieving standards, and getting all-important reimbursement codes.
Investor relations – a start-up can’t survive without regular infusions of capital. So keeping investors happy–and focused on a success that may be years in the making–is critical. Communication and transparency are the rules. It’s just as important to understand their need for revenue. Show them a path to profitability. Create multiple plans for success. Tell them where you see opportunities for growth. And toot your horn when you find pockets of success.
Longeviti is a great story that truly captures the med-tech entrepreneurial spirit. And the discussion is chock-full of great info.
Helpful Links:
www.longeviti.com
www.hydroassoc.org/hydrocephalus/
Coagusense developed the first point-of-care prothrombin time/Internationalized Normalized Ratio (PT/INR) monitoring system for cardiac patients to help them maintain warfarin dosage within a therapeutic range. In the latest version of their device, they actually removed connectivity features to accommodate the needs of their older, less-tech-savvy self-testers. Therefore, they had to go back to the FDA with more bench data for re-approval.
Andy Rogers talked with Mike Acosta, EVP/Head of Compliance at Coagusense, and later recapped some of the lessons learned with Senior Electrical Engineer Jake Cowperthwaite. Andy and Jake have an informative discussion about how to define performance requirements when you’re aiming for FDA approval.
Need to know:
The nitty gritty:
Rule Number One is to make sure that the performance of the device is objectively verifiable. For example, simply stating “the device shall be easy to use” is vague and subjective and won’t cut it with the FDA.
Write your requirement in a way that can be verified through: testing and measuring results, a functional demonstration of performance, analysis via calculations or simulations, or visual inspection. A well-written requirement is specific with clear criteria, for example if your product was a pump, a performance requirement could be: “the aspiration pump shall have X flow rate within Y bounds”. If it meets that requirement, you’re ready to move on. Don’t over-spec.
Three things the FDA is looking for:
At the test bench, start with a good understanding of how many prototypes you’ll need to have statistical confidence in your results. Sample size will depend on the data needed; an on/off switch won’t require a large sample size, but testing with different operators – as with in-home devices – will need a substantial data set.
In some cases, it’s possible to short-cut the process early in development by testing multiple variables at once. This will yield a lot of data, which can then be analyzed. You’ll find some variables meaningful and others not, but understanding these variables and their sensitivity early in product development has great value and can save money in producing fewer prototypes.
USEFUL LINKS
https://coag-sense.com/about-us/
https://www.greenlight.guru/
There’s nothing like finding a partner with a map when you're exploring new territory.
CoaguSense developed the first point-of-care prothrombin time/Internationalized Normalized Ratio (PT/INR) monitoring system for cardiac patients who have been prescribed warfarin. Their Coag-Sense® device monitors blood clotting rates and helps patients maintain rates within a therapeutic range. It’s designed for both professionals and patient self-testers. As with any MedTech device, there were plenty of regulatory hoops to jump through. So they looked for outside help and found it with Greenlight Guru, a company that provides an out-of-the-box electronic quality management system specifically designed for MedTech companies.
Listen in as Andy Rogers talks with Mike Acosta, EVP/Head of Compliance, CoaguSense, and Wade Schroeder, Medical Device Guru at Greenlight Guru, to learn how outsourcing can facilitate speed to data and get you to market more efficiently.
NEED TO KNOW:
THE NITTY-GRITTY:
According to the FDA, about two million people in the United States take warfarin to prevent blood clots and to prevent stroke in people with atrial fibrillation, heart disease, or artificial heart valves.
So CoaguSense was poised to capitalize on a large market. But as a small company with a new technology, the path to regulatory approval could have been long, tortuous, and costly.
Greenlight Guru came to the table with a purpose-built platform that could manage all the quality, regulatory, clinical, and product development activities across the entire device lifecycle. And having the design control aspect upfront helps all the way.
Coag-Sense is now a market leader, and they’re working on a 3rd Gen simpler version to meet the needs of their older patients. Every step of the way, data drove the decisions.
Fast data. The Coag-Sense® meter directly measures clot formation in seconds.
Procedures and templates from Greenlight Guru were audit-ready to align with regulations, including ISO 13485 and FDA CFR Part 820, and provide a traceable source of truth.
Independent diagnostic testing facilities (IDTFs) can be used to manage call-in results from self-testers, even if a device lacks connectivity.
Developing a “downgraded” next-gen version without connectivity for elderly patients
The Gen 3 version of Coag-Sense actually has fewer bells and whistles in response to the needs of older in-home self-testers who are less tech-savvy. Here are the hows and whys:
Consider elderly patients' desire for simple devices - Many older people don’t have computers at home or are not savvy with smartphones; they don’t want or need connectivity. These patients are more commonly managed by IDTF’s who can manage self-testers.
Build in time for FDA reviews - First, a Gen 3 FDA review is more challenging than a Gen 2 review. You’ll need to show more performance data: FDA wants to see data comparing operator to operator. In addition, the classic 30-day review for 510k is now taking almost a year, with older reviewers retiring and new reviewers coming on board.
Be ready with a plan for post-market surveillance - IVDR - Capturing post-market surveillance data is required now and will feed back for potential improvements.
Find partners who continually evolve – CoaguSense partnered with Greenlight for an out-of-the-box solution for QMS & documents, but just as important for keeping up with what needs to be reviewed in international markets and traceability mapping too.
It all adds up to one interesting discussion. Listen in.
USEFUL LINKS:
https://coag-sense.com/about-us/
https://www.greenlight.guru/
From the publisher's feed